Scancell Holdings plc (AIM:SCLP)

Market Cap	113.00M
Revenue (ttm)	n/a
Net Income (ttm)	-15.81M
Shares Out	1.03B
EPS (ttm)	-0.02
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	687,143
Average Volume	1,323,619
Open	9.95
Previous Close	10.50
Day's Range	9.50 - 10.37
52-Week Range	7.26 - 19.75
Beta	0.08
RSI	71.76
Earnings Date	Sep 24, 2025

About Scancell Holdings

Scancell Holdings plc, a clinical stage biopharmaceutical company, engages in the discovery and development of novel immunotherapies and vaccines for the treatment of cancer and infectious disease. Its product candidates include SCIB1, an ImmunoBody cancer vaccine that is in Phase II for the treatment of metastatic melanoma; and SCIB2/iSCIB2 vaccine, which is under evaluation for the treatment of patients with solid tumors, including non-small cell lung cancer. It also develops Modi-1, a citrullinated peptides vaccine that is in phase I/II clin...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 1997
• Employees: 61
• Stock Exchange: London Stock Exchange AIM
• Ticker Symbol: SCLP